Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Other
    • ASN Publications
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • ASN Publications
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Follow JASN on Twitter
  • Visit ASN on Facebook
  • Follow JASN on RSS
  • Community Forum
Research Letters
Open Access

The Exclusion of Patients with CKD in Prospectively Registered Interventional Trials for COVID-19—a Rapid Review of International Registry Data

Rupert Major, Haresh Selvaskandan, Yahya Mostafa Makkeyah, Katherine Hull, Apexa Kuverji and Matthew Graham-Brown
JASN October 2020, 31 (10) 2250-2252; DOI: https://doi.org/10.1681/ASN.2020060877
Rupert Major
1Department of Health Sciences, University of Leicester, Leicester, United Kingdom
2John Walls Renal Unit, Leicester General Hospital, University Hospitals of Leicester, Leicester, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Rupert Major
Haresh Selvaskandan
2John Walls Renal Unit, Leicester General Hospital, University Hospitals of Leicester, Leicester, United Kingdom
3Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Haresh Selvaskandan
Yahya Mostafa Makkeyah
2John Walls Renal Unit, Leicester General Hospital, University Hospitals of Leicester, Leicester, United Kingdom
4Internal Medicine and Nephrology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Yahya Mostafa Makkeyah
Katherine Hull
2John Walls Renal Unit, Leicester General Hospital, University Hospitals of Leicester, Leicester, United Kingdom
3Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Katherine Hull
Apexa Kuverji
2John Walls Renal Unit, Leicester General Hospital, University Hospitals of Leicester, Leicester, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew Graham-Brown
2John Walls Renal Unit, Leicester General Hospital, University Hospitals of Leicester, Leicester, United Kingdom
3Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading
  • clinical trial
  • chronic kidney disease
  • COVID-19

The exclusion of patients with CKD from clinical trials has been a barrier to therapeutic advancement in CKD for the last two decades.1 These inequities were highlighted by the Kidney Disease Improving Global Outcomes Controversies Conference, with the ambition of ensuring that individuals with CKD are included in relevant clinical trials.2 The coronavirus disease 2019 (COVID-19) pandemic’s global effect has led to rapid clinical trial registration and commencement in search of effective treatments. Individuals with CKD are at higher risk of COVID-19–related mortality.3 It is unclear, however, if these individuals have equitable access to clinical trial recruitment. Therefore, we aimed to assess the CKD-related inclusion and exclusion criteria for COVID-19 trials.

Methods

We assessed inclusion and exclusion criteria of all registered interventional clinical trials for COVID-19 from data available on the World Health Organization International Clinical Trials Registry Platform4 (WHO-ICTRP; data extracted April 22nd, 2020). Clinical trials were divided into “pharmaceutical” and “nonpharmaceutical” trials. The former was defined as any medication that would be regulated by the Food and Drug Administration or a similar regulatory body. All other trials were classified as nonpharmacologic, including “traditional Chinese medicine” clinical trials. Interventions and exclusion criteria for each trial were independently reviewed and extracted by two assessors blinded to other trial details. Pharmaceutical intervention suitability for patients with CKD was independently assessed by two blinded specialist renal pharmacists using summary of product characteristics (equivalent of United States prescribing information), British National Formulary5 and the Renal Drug Database.6 The study’s primary analysis considered trial exclusions for any type of nonend stage and end stage CKD. AKI was assessed for this analysis.

Results and Discussion

In total, 484 trials were identified from WHO-ICTRP and included in the analysis as shown in Figure 1; 364 pharmaceutical trials testing 120 different medications were identified (Supplemental Material). The trials’ core characteristics are shown in Table 1. Forty (33.3%) medications either were contraindicated or had insufficient data available to assess their suitability in CKD. Twenty-five medications (20.8%) were categorized as appropriate for use in CKD with caution. In total, 218 (45.0%) trials had exclusion criteria on the basis of CKD. Sixty-three (13.0%) trials excluded CKD but gave an unclear or vague description of CKD, such as “kidney dysfunction.” Additionally, 189 (51.9%) of the clinical trials were classified by the investigators as “late-phase” (2b, 3, or 4) clinical trials. The most common intervention that excluded individuals with CKD was chloroquine/hydroxychloroquine in 59 pharmaceutical trials (52.7%).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Registry sources of the COVID-19 trials identified and their classification by interventional category flowchart. ANZCTR, Australian New Zealand Clinical Trials Registry; ChiCTR, Chinese Clinical Trial Registry; IRCT, Iranian Registry of Clinical Trials; ISRCTN, International Standard Randomised Controlled Trial Number; JPRN, Japan Primary Registries Network; WHO, World Health Organization.

View this table:
  • View inline
  • View popup
Table 1.

Trial descriptors

Factors associated with exclusion of individuals with CKD were assessed using binary logistic regression and are presented in Supplemental Table 1. Pharmaceutical trials involving participants from China, particularly those testing chloroquine/hydroxychloroquine, antivirals, and antibacterials, were more likely to exclude individuals with CKD, whereas those from Europe were less likely.

These data suggest that patients with CKD are being excluded from almost half of all registered clinical trials for COVID-19. For the pharmaceutical compounds being tested, there were few pharmacologic reasons why patients with CKD should have been excluded from the studies reviewed. These findings raise concerns that patients with CKD and the clinicians looking after them may be left without an adequate evidence base from which to offer tested treatments to a group of patients known to be at risk of the worst outcomes from COVID-19. The majority of the trial pharmaceutical compounds have well-understood pharmacokinetic and pharmacodynamics properties and are used in CKD. For instance, hydroxychloroquine is a mainstay of treatment for patients with lupus who have CKD.7 Inconsistencies were also noted in the definition of CKD used in trials; 13% of trials’ exclusion criteria had no specific CKD definition, with terms such as “kidney disease” or “kidney dysfunction” used. Potential participants with more advanced CKD stages were more likely to be excluded, with approximately a third of trials excluding those on dialysis and a similar number of transplant recipients. This suggests that inclusivity of future COVID-19 trials in relation to CKD could be improved through more precise CKD definitions and consideration of medication appropriateness, perhaps with dose adjustments where applicable.

The reasons for the international differences in exclusion of patients with CKD from trials are not clear but may related to the pandemic’s global evolution or differing understandings of CKD’s classification and implications. Because of the time-sensitive nature of this analysis, we did not prospectively register this study, and this may be regarded as a limitation.8 However, this potential bias was minimized by blinding and duplicating all assessments to the trials’ characteristics. A further weakness was that a trial’s exclusion criteria were directly on the basis of those reported to WHO-ICTRP, and we did not perform analysis from a trial’s published protocol.

The scientific community has a responsibility to build an evidence base for the treatment of all patients with COVID-19, including those with CKD who may be the most clinically vulnerable. This highly time-sensitive matter must be addressed by investigators, regulators, and the nephrology community to improve clinical trial design and enhance equitable access to new treatments and trial inclusion for patients with CKD.

Disclosures

All authors have nothing to disclose.

Funding

M. Graham-Brown is funded by a National Institute for Health Research Academic Clinical Lectureship award. K. Hull is funded by a National Institute for Health Research Academic Clinical Fellow award. H. Sekvaskandan is funded by Kidney Research UK grant TF_009_20181123.

Acknowledgments

The authors acknowledge the full contribution of the following individuals in relation to this project—blinded assessment of trial data: Dr. Terrina Abd Rahim, Dr. Abubaker Obeidalla, Dr. Ismet Boral, Mr. Robert Grant, Dr. Susil Pallikadavath, and Dr. Jorge Jesus-Silva; blinded assessment of medication data: Mr. Dipesh Patel and Ms. Amy Page; and development of research idea and redrafting of manuscript: Prof. Nigel Brunskill.

The views expressed are those of the authors and not necessarily those of the National Health Service, the National Institute for Health Research, the Department of Health and Social Care, or Kidney Research UK.

Matthew Graham-Brown, Rupert Major, Yahya Mostafa Makkeyah, and Haresh Sekvaskandan developed the research idea; Yahya Mostafa Makkeyah performed data extraction; Rupert Major performed data processing; Matthew Graham-Brown, Katherine Hull, Apexa Kuverji, and Haresh Sekvaskandan performed blinded assessment of data; Rupert Major performed statistical analysis; Rupert Major wrote the initial draft of the manuscript; Matthew Graham-Brown and Rupert Major redrafted the manuscript; and all authors approved the final manuscript.

Supplemental Material

This article contains the following supplemental material online at http://jasn.asnjournals.org/lookup/suppl/doi:10.1681/ASN.2020060877/-/DCSupplemental.

Supplemental Material. Supplemental data.

Supplemental Table 1. Risk factors for CKD exclusion from pharmaceutical clinical trials for patients with COVID-19. Intervention comparator is nonpharmaceutical trials.

Footnotes

  • Published online ahead of print. Publication date available at www.jasn.org.

  • Copyright © 2020 by the American Society of Nephrology

References

  1. ↵
    1. Strippoli GF,
    2. Craig JC,
    3. Schena FP
    : The number, quality, and coverage of randomized controlled trials in nephrology. J Am Soc Nephrol 15: 411–419, 2004 pmid:14747388
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Baigent C,
    2. Herrington WG,
    3. Coresh J,
    4. Landray MJ,
    5. Levin A,
    6. Perkovic V, et al; KDIGO Controversies Conference on Challenges in the Conduct of Clinical Trials in Nephrology Conference Participants
    : Challenges in conducting clinical trials in nephrology: Conclusions from a Kidney Disease-Improving Global Outcomes (KDIGO) controversies conference. Kidney Int 92: 297–305, 2017 pmid:28709600
    OpenUrlCrossRefPubMed
  3. ↵
    1. Williamson EJ,
    2. Walker AJ,
    3. Bhaskaran K,
    4. Bacon S,
    5. Bates C,
    6. Morton CE, et al
    : Factors associated with COVID-19-related death using OpenSAFELY. Nature 584: 430–436, 2020
    OpenUrlCrossRefPubMed
  4. ↵
    World Health Organization: International Clinical Trials Registry Platform (ICTRP), 2020. Available at: https://www.who.int/ictrp/en/. Accessed April 22, 2020
  5. ↵
    MedicinesComplete: The definitive online resource for drug and healthcare information, 2020. Available at: http://www.medicinescomplete.com. Accessed May 27, 2020
  6. ↵
    The Renal Drug Database: The ultimate prescribing guide for renal practitioners, 2020. Available at: https://renaldrugdatabase.com. Accessed May 27, 2020
  7. ↵
    1. Lee SJ,
    2. Silverman E,
    3. Bargman JM
    : The role of antimalarial agents in the treatment of SLE and lupus nephritis. Nat Rev Nephrol 7: 718–729, 2011 pmid:22009248
    OpenUrlCrossRefPubMed
  8. ↵
    National Institute of Health Research: PROSPERO: International prospective register of systematic reviews, 2020. Available at: https://www.crd.york.ac.uk/prospero/. Accessed May 27, 2020
PreviousNext
Back to top

In this issue

Journal of the American Society of Nephrology: 31 (10)
Journal of the American Society of Nephrology
Vol. 31, Issue 10
October 2020
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in JASN.
Enter multiple addresses on separate lines or separate them with commas.
The Exclusion of Patients with CKD in Prospectively Registered Interventional Trials for COVID-19—a Rapid Review of International Registry Data
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The Exclusion of Patients with CKD in Prospectively Registered Interventional Trials for COVID-19—a Rapid Review of International Registry Data
Rupert Major, Haresh Selvaskandan, Yahya Mostafa Makkeyah, Katherine Hull, Apexa Kuverji, Matthew Graham-Brown
JASN Oct 2020, 31 (10) 2250-2252; DOI: 10.1681/ASN.2020060877

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
The Exclusion of Patients with CKD in Prospectively Registered Interventional Trials for COVID-19—a Rapid Review of International Registry Data
Rupert Major, Haresh Selvaskandan, Yahya Mostafa Makkeyah, Katherine Hull, Apexa Kuverji, Matthew Graham-Brown
JASN Oct 2020, 31 (10) 2250-2252; DOI: 10.1681/ASN.2020060877
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Methods
    • Results and Discussion
    • Disclosures
    • Funding
    • Acknowledgments
    • Supplemental Material
    • Footnotes
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Second Wave Antibodies in Autoimmune Renal Diseases: The Case of Lupus Nephritis
  • Patient Activation Measure in Dialysis-Dependent Patients in the United States
  • Use of a Smartphone Camera at the Bedside to Assess Adequacy of Kidney Biopsies
Show more Research Letters

Cited By...

  • COVID-19 and AKI: Where Do We Stand?
  • Google Scholar

Similar Articles

Related Articles

  • PubMed
  • Google Scholar

Keywords

  • clinical trial
  • chronic kidney disease
  • COVID-19

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Annual Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • Editorial Fellowship Program
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • JASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About JASN
  • JASN Email Alerts
  • JASN Key Impact Information
  • JASN Podcasts
  • JASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe to ASN Journals
  • Wolters Kluwer Partnership

© 2022 American Society of Nephrology

Print ISSN - 1046-6673 Online ISSN - 1533-3450

Powered by HighWire